Current and Future Perspectives of PDL1 PET and SPECT Imaging

• Published in: Seminars in nuclear medicine 2024-11, Vol.54 (6), p.966-975
• Main Authors: Dev, Indraja D., Puranik, Ameya D., Singh, Baljinder, Prasad, Vikas
• Format: Article
• Language: English
• ISSN: 0001-2998; 1558-4623; 1558-4623
• DOI: 10.1053/j.semnuclmed.2024.09.008

Programmed Death 1 (PD1) and Programmed Death Ligand (PDL1) play a crucial role in tumor microenvironment by helping cancer cells evade innate immunity. Numerous inhibitor anticancer drugs targeting this interplay have been used in clinical practice and many more are in preclinical stage. These drugs have shown promising results in achieving good response and long-term clinical benefit, is routinely performed to identify patients who may benefit. However, there are major challenges associated with these immunohistochemistry tests which have opened the space for noninvasive imaging modalities using PD1 and PDL1 inhibitors labeled with either PET or SPECT radionuclides. These radiopharmaceuticals, although primarily developed for the field of immunotherapy, have great potential in expanding and optimizing the combination of radiopharmaceutical therapies with PD1-PDL1 targeting anticancer drugs. This review elaborates currently available PET and SPECT radiopharmaceuticals targeting PD1-PDL1 axis. It also explores the potential future role of newer targets which are being developed and tested in various preclinical studies.